Xeris Biopharma Holdings, Inc. Files Definitive Proxy Statement

TL;DR

<b>Xeris Biopharma Holdings, Inc. has filed a Definitive Proxy Statement (DEF 14A) on April 23, 2024.</b>

AI Summary

Xeris Biopharma Holdings, Inc. (XERS) filed a Proxy Statement (DEF 14A) with the SEC on April 23, 2024. Filing type is DEF 14A, filed on 2024-04-23. Reporting period is 2024-06-05. Company address: 1375 West Fulton Street, Suite 1300, Chicago, IL 60607. Business phone: 844-445-5704. Fiscal year end is December 31.

Why It Matters

For investors and stakeholders tracking Xeris Biopharma Holdings, Inc., this filing contains several important signals. This filing indicates the company is preparing for its annual shareholder meeting, where key corporate decisions and director elections will take place. The DEF 14A filing provides detailed information on executive compensation, stock ownership, and other governance matters, which are crucial for investors to understand before voting.

Risk Assessment

Risk Level: low — Xeris Biopharma Holdings, Inc. shows low risk based on this filing. The filing is a routine DEF 14A, providing information on corporate governance and executive compensation, with no immediate financial or operational disclosures that would suggest high risk.

Analyst Insight

Review the proxy statement for details on executive compensation, board nominations, and any shareholder proposals to inform voting decisions.

Key Numbers

• 2024-04-23 — Filing Date (Date the DEF 14A was filed)
• 2024-06-05 — Period of Report (The period for which the filing is made)
• 1231 — Fiscal Year End (The company's fiscal year end date)
• 844-445-5704 — Business Phone (Company contact phone number)

Key Players & Entities

• Xeris Biopharma Holdings, Inc. (company) — Filer name
• 1375 West Fulton Street, Suite 1300 (location) — Company business address
• Chicago (location) — Company business city
• IL (location) — Company business state
• 60607 (location) — Company business zip code

FAQ

Industry Context

Xeris Biopharma Holdings, Inc. operates in the pharmaceutical preparations industry.

Regulatory Implications

The filing is a DEF 14A, which is a standard SEC filing for companies soliciting proxies from shareholders.

What Investors Should Do

1. Review the proxy statement for details on director nominees and their qualifications.
2. Analyze the executive compensation section to understand pay structures and potential incentives.
3. Examine any shareholder proposals and management's recommendations for voting.

Year-Over-Year Comparison

This is a DEF 14A filing, which is a routine disclosure for annual shareholder meetings and does not represent a change from previous filings of the same type.

Key Financial Figures

• $40,000 — ments, which are not expected to exceed $40,000. In addition, we have hired Innisfree M
• $25,000 — ments, which are not expected to exceed $25,000. When is the record date for the Annua
• $0.0001 — s hares of our common stock, par value $0.0001 per share, outstanding on April 12, 202

Filing Documents

• xers-20240423.htm (DEF 14A) — 841KB
• xers-20240423_g1.jpg (GRAPHIC) — 16KB
• xers-20240423_g2.jpg (GRAPHIC) — 36KB
• xers-20240423_g3.jpg (GRAPHIC) — 11KB
• xers-20240423_g4.jpg (GRAPHIC) — 33KB
• xers-20240423_g5.jpg (GRAPHIC) — 78KB
• xers-20240423_g6.jpg (GRAPHIC) — 71KB
• xers-20240423_g7.jpg (GRAPHIC) — 75KB
• xers-20240423_g8.jpg (GRAPHIC) — 2528KB
• xers-20240423_g9.jpg (GRAPHIC) — 550KB
• 0001867096-24-000053.txt (&nbsp;) — 9704KB
• xers-20240423.xsd (EX-101.SCH) — 1KB
• xers-20240423_htm.xml (XML) — 123KB

EXECUTIVE COMPENSATION 24

EXECUTIVE COMPENSATION 24 DIRECTOR COMPENSATION 45 RELATED PERSON TRANSACTION POLICY AND PROCEDURES 46 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 47 PRINCIPAL STOCKHOLDERS 49 DELINQUENT SECTION 16(A) REPORTS 51 REPORT OF THE AUDIT COMMITTEE 52 HOUSEHOLDING 53 STOCKHOLDER PROPOSALS 53 OTHER MATTERS 53 FIRST AMENDMENT TO THE XERIS PHARMACEUTICALS, INC. 2018 EMPLOYEE STOCK PURCHASE PLAN 54 This document includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical or current facts, including statements regarding our plans and goals, made in this document are forward-looking. We use words such as anticipates, believes, expects, future, intends, and similar expressions to identify forward-looking statements. Forward-looking statements reflect management's current expectations and are inherently uncertain. Actual results could differ materially for a variety of reasons. Risks and uncertainties that could cause our actual results to differ significantly from management's expectations are described in our 2023 Annual Report on Form 10-K. Website references throughout this document are provided for convenience only, and the content on the referenced websites is not incorporated by reference into this document. A copy of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as filed with the Securities and Exchange Commission, except for exhibits, will be furnished without charge to any stockholder upon written request to Xeris Biopharma Holdings, Inc., 1375 West Fulton Street, Suite 1300, Chicago, Illinois 60607, Attention: Corporate Secretary. This proxy statement and our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 are also available on the SEC's website at www.sec.gov . XERIS BIOPHARMA HOLDINGS, INC. PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD JUNE 5, 2024 GE

View Full Filing

View this DEF 14A filing on SEC EDGAR